Oral Cancer Risk Factors Molecular Changes and Treatment

Posted on November 9, 2024

Introduction

Oral cancer is not a single disease of the entire throat and mouth but a group of malignant tumors that arise in anatomically distinct sites. The oral cavity includes the lips, the front two-thirds of the tongue, the gums, the inner cheek lining, the floor of the mouth, the hard palate, and the retromolar area behind the wisdom teeth. Cancers arising in the tonsils and the base of the tongue are classified as oropharyngeal cancers and differ from oral-cavity cancers in their biology, risk profile, staging, and response to treatment. Most malignant tumors in both regions are squamous cell carcinomas, but accurately identifying the primary site is essential because an HPV-associated tonsillar cancer is not clinically equivalent to a tobacco-associated cancer of the floor of the mouth. (National Cancer Institute, n.d.)

The original discussion correctly identified tobacco, alcohol, persistent lesions, genetic disruption, angiogenesis, lymphatic spread, imaging, targeted treatment, and immunotherapy as important topics. A fuller account, however, must connect these elements into one disease process: carcinogenic exposure and inherited susceptibility produce molecular injury; selected cell populations escape normal growth control; the tumor recruits blood vessels and invades surrounding tissue; malignant cells reach cervical lymph nodes or distant organs; and diagnosis, stage, pathology, functional needs, and patient preferences determine treatment. Oral cancer therefore requires both molecular understanding and multidisciplinary care. (National Cancer Institute, n.d.; Knopf et al., 2015; Sakata et al., 2019)

Risk Factors and Prevention

Tobacco exposure remains one of the most important modifiable risks. Cigarettes, cigars, pipes, smokeless tobacco, and areca or betel-quid products expose oral tissues to carcinogens that damage DNA and promote chronic inflammation. Alcohol independently raises risk and acts synergistically with tobacco, so combined heavy use is substantially more dangerous than either exposure alone. Other relevant factors include increasing age, ultraviolet exposure for lip cancer, poor nutrition, immunosuppression, previous head-and-neck cancer, and certain occupational or environmental exposures. Social conditions also matter because limited access to dental care, preventive services, transportation, and specialist evaluation can delay diagnosis. (National Cancer Institute, n.d.)

Human papillomavirus requires anatomical precision. Persistent infection with high-risk HPV,

especially HPV-16, is strongly associated with cancers of the oropharynx, particularly the tonsils and base of the tongue. HPV is a much less dominant cause of cancers arising in the anterior oral cavity. This distinction prevents a common error in which every “mouth cancer” is described as HPV-driven. HPV vaccination can prevent infections responsible for several cancers and is therefore an important population-level prevention strategy, but it does not replace tobacco cessation, alcohol-risk reduction, oral examination, or timely investigation of suspicious lesions. (National Cancer Institute, n.d.)

Clinical Presentation and Diagnostic Evaluation

Early oral-cavity cancer may be painless. Warning signs include a sore that does not heal, a persistent red or white patch, a firm lump, unexplained bleeding, numbness, pain, loosening of teeth, reduced tongue movement, difficulty chewing or swallowing, a change in speech, or a neck mass. Symptoms lasting about two weeks warrant professional evaluation, although an urgent assessment may be appropriate sooner when a lesion is rapidly enlarging, bleeding, or associated with airway or swallowing problems. Persistent bad breath and weight loss can occur but are nonspecific and should not be treated as diagnostic by themselves. (National Cancer Institute, n.d.)

Diagnosis begins with a careful history and inspection and palpation of the oral cavity, oropharynx, and neck. A suspicious lesion requires tissue biopsy; imaging cannot substitute for histopathology. Computed tomography or magnetic resonance imaging helps define local invasion and cervical-node involvement, while positron-emission tomography combined with CT may assist in selected advanced cases or when an occult primary or distant disease is suspected. Pathology identifies tumor type, differentiation, depth of invasion, margins, perineural or lymphovascular invasion, and nodal features. For appropriate oropharyngeal tumors, HPV-related testing, commonly through p16 immunohistochemistry with confirmatory interpretation, has prognostic and staging significance. (National Cancer Institute, n.d.)

Oncogenes and Tumor-Suppressor Pathways

Oral squamous cell carcinoma develops through accumulated genomic and epigenetic changes rather than one universal mutation. *TP53* is a central tumor-suppressor gene. Its protein normally coordinates DNA-damage responses, cell-cycle arrest, senescence, and apoptosis. Loss or alteration of this pathway allows genetically damaged cells to continue dividing. Tobacco-associated head-and-neck cancers frequently contain disruptive *TP53* changes, whereas HPV-positive oropharyngeal cancers often disable p53 through the viral E6 protein instead of following the same mutation pattern. (Knopf et al., 2015)

CDKN2A encodes proteins involved in cell-cycle control, including p16. Deletion, mutation, or promoter methylation can remove an important brake on progression from the G1 to S phase. By contrast, strong p16 expression in an oropharyngeal tumor may serve as a marker of HPV-associated

biology, demonstrating why one laboratory finding can have different meanings depending on anatomical site and mechanism. Additional alterations may affect *NOTCH1*, *FAT1*, *PIK3CA*, *CASP8*, and pathways involving EGFR, RAS, PI3K-AKT-mTOR, and cell adhesion. *HRAS* mutations occur in a subset of oral cancers but are not confined to lip tumors and should not be presented as the defining change for the disease. (Knopf et al., 2015)

Molecular information increasingly supports clinical-trial selection and, in some advanced settings, targeted treatment. Nevertheless, routine care is still driven primarily by site, stage, pathology, resectability, functional consequences, performance status, and biomarker findings that have demonstrated clinical value. A mutation discovered in a research study is not automatically an approved therapeutic target. (National Cancer Institute, n.d.)

Angiogenesis, Invasion, and Metastasis

As a tumor grows, diffusion alone cannot supply adequate oxygen and nutrients. Cancer cells and stromal cells respond to hypoxia by increasing pro-angiogenic signals such as vascular endothelial growth factor. Newly formed vessels support growth but are often irregular and permeable. Angiogenesis interacts with inflammation, extracellular-matrix remodeling, and immune evasion; it is therefore part of a broader tumor microenvironment rather than an isolated event. (Sakata et al., 2019)

Local invasion can damage the tongue, jaw, skin, nerves, and swallowing structures. Tumor cells may reduce adhesion, degrade surrounding matrix, and acquire greater motility. The most common first route of spread is through lymphatics to cervical lymph nodes. Depth of invasion in oral-cavity tumors helps predict nodal risk, while extranodal extension—tumor growing beyond the capsule of an involved lymph node—has major prognostic and treatment implications. Distant metastases are less common at presentation than regional spread but may develop in the lungs, bones, liver, or other organs in advanced disease. Nodal status, margin status, primary-tumor extent, and distant spread are therefore central to staging and prognosis. (National Cancer Institute, n.d.; Sakata et al., 2019)

Treatment and Supportive Care

For many resectable oral-cavity cancers, surgery is the primary treatment. Depending on location and stage, this may involve local excision, partial removal of the tongue or jaw, neck dissection, and reconstructive surgery. Radiation may be used after surgery when pathology shows higher-risk features, and concurrent chemoradiation may be recommended for selected very high-risk findings such as positive margins or extranodal extension. Definitive radiation-based treatment is more common for certain oropharyngeal cancers, where organ preservation may be possible. Treatment planning must distinguish evidence-based de-intensification research from standard care; favorable HPV-associated biology does not mean that therapy should be reduced outside appropriate protocols.

(National Cancer Institute, n.d.)

Recurrent or metastatic head-and-neck squamous cell carcinoma may be treated with platinum-based regimens, cetuximab in selected contexts, and immune-checkpoint inhibitors targeting the PD-1 pathway, with decisions influenced by previous therapy, disease burden, symptoms, biomarker results, and general health. “Targeted therapy” and “immunotherapy” should not be described as universally curative. They can produce meaningful responses for some patients, but resistance and adverse effects remain important. (National Cancer Institute, n.d.)

Comprehensive care includes dental evaluation before radiation, smoking and alcohol support, pain control, nutritional management, speech and swallowing therapy, management of dry mouth, psychosocial care, and rehabilitation after surgery. Survivorship includes monitoring for recurrence, second primary tumors, thyroid dysfunction after neck irradiation, dental complications, and long-term functional effects. Shared decision-making is essential because two treatments with similar cancer control may differ significantly in speech, swallowing, appearance, employment, and quality of life. (National Cancer Institute, n.d.)

Prognosis, Screening, and Equity

Prognosis depends strongly on stage at diagnosis, primary site, depth of invasion, lymph-node status, extranodal extension, margins, general health, and the feasibility of completing treatment. Population screening for every asymptomatic adult has not been proven to reduce mortality in all settings, but opportunistic examination by dental and medical professionals is valuable, especially for people with major risk exposures or suspicious symptoms. Self-examination can increase awareness but cannot reliably distinguish cancer from trauma, infection, inflammatory disease, or benign lesions. (National Cancer Institute, n.d.)

Late diagnosis is often shaped by more than individual delay. Cost, lack of dental coverage, fragmented referral pathways, geographic distance, stigma, fear of disfigurement, and limited access to specialists can extend the time between first symptom and biopsy. Prevention and early-detection strategies should therefore include tobacco and alcohol services, HPV vaccination, accessible oral health care, rapid referral, culturally appropriate communication, and financial support during treatment. Improving outcomes requires reducing these system barriers alongside developing new drugs. (National Cancer Institute, n.d.)

Limits of Molecular Personalization

Precision oncology has expanded the vocabulary of oral-cancer care, but molecular profiling must be interpreted cautiously. Tumors are heterogeneous, and a sample from one region may not capture every resistant clone. A detected alteration may be biologically interesting without being actionable, and a drug effective in another cancer type may not work in oral squamous cell carcinoma. Testing is

most useful when it answers a defined clinical question, follows validated laboratory standards, and connects the patient to an approved therapy or a well-designed clinical trial. (Knopf et al., 2015; National Cancer Institute, n.d.)

Ethical implementation also requires attention to cost, informed consent, incidental hereditary findings, data privacy, and unequal access. Molecular innovation should complement—not displace—basic needs such as prompt biopsy, high-quality surgery, radiation planning, nutrition, rehabilitation, and supportive care.

Conclusion

Oral cancer is best understood as a site-specific squamous malignancy shaped by exposure, molecular disruption, local anatomy, and patterns of lymphatic spread. Tobacco and alcohol are major preventable risks, while high-risk HPV is particularly important for oropharyngeal—not all oral—cancers. Changes involving *TP53*, *CDKN2A*, growth-signaling pathways, adhesion, and immune regulation help explain malignant progression, but biopsy and anatomical staging remain indispensable. Earlier recognition of persistent lesions, precise diagnosis, appropriate surgery or radiation, systemic therapy when indicated, and sustained rehabilitation offer the strongest path to improved survival and function. (National Cancer Institute, n.d.; Knopf et al., 2015; Sakata et al., 2019)

References

National Cancer Institute. *Lip and Oral Cavity Cancer Treatment (PDQ®)*. https://www.cancer.gov/types/head-and-neck/patient/adult/lip-mouth-treatment-pdq

National Cancer Institute. *Oral Cavity, Oropharyngeal, Hypopharyngeal, and Laryngeal Cancers Prevention (PDQ®)*. https://www.cancer.gov/types/head-and-neck/hp/oral-prevention-pdq

National Cancer Institute. *Oropharyngeal Cancer Treatment (PDQ®)*. https://www.cancer.gov/types/head-and-neck/hp/adult/oropharyngeal-treatment-pdq

Knopf, A., et al. (2015). Oncogenes and tumor suppressor genes in squamous cell carcinoma of the tongue in young patients. *Oncotarget, 6*(5), 3443–3451.

Sakata, J., et al. (2019). HMGA2 contributes to distant metastasis and poor prognosis by promoting angiogenesis in oral squamous cell carcinoma. *International Journal of Molecular Sciences, 20*(10), 2473.